Recombinant Mouse Midkine protein (mFc Tag)

• Home
• Products
• Fusion Proteins
• AuthentiKine ELISA Kits
• Recombinant Mouse Midkine protein (mFc Tag) (Eg3927)

Species

Mouse

Purity

>90 %, SDS-PAGE

Tag

mFc Tag

Activity

not tested

Cat no : Eg3927

---

Validation Data Gallery

• 

  Purity of Recombinant Mouse Midkine was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Mouse Mdk protein Lys23-Asp140 (Accession# P12025) with a mouse IgG Fc tag at the C-terminus.
• GeneID: 17242
• Accession: P12025
• PredictedSize: 39.7 kDa
• SDS-PAGE: 42-48 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Midkine (MK) is a heparin-binding growth factor and a cytokine, identified as a product of a retinoic acid-responsive gene involved in embryonic development. MK promotes cell survival, migration, differentiation, and growth, and is involved in various physiological and pathological processes such as neuronal development, tissue repair, inflammation, and malignancies. It is upregulated in numerous injured tissues and most human malignant tumors, suggesting its role in tissue repair and cancer progression. It also has been implicated in Alzheimer's disease, with increased levels in sera from patients, and is being explored as a potential biomarker and therapeutic target in various diseases.

References:

1.Muramatsu T. et al. (2010). Proc Jpn Acad Ser B Phys Biol Sci. 86(4):410-425. 
2.Cai YQ. et al. (2020). Cytokine. 135:155242. 
3.Weckbach LT. et al. (2011). ScientificWorldJournal. 11:2491-2505. 
4.Jones DR. et al. (2014). Br J Pharmacol. 171(12):2925-2939.
5.Filippou PS. et al. (2020). Oncogene. 39(10):2040-2054.